Scientific and Legal Viability of Follow-on Protein Drugs  

Oleh:

Dudzinski, David M. ; Kesselheim, Aaron S.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 358 no. 08 (Feb. 2008), page 843.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Since recombinant human insulin (Humulin) became the first recombinant-protein drug approved by the Food and Drug Administration (FDA) 25 years ago, nearly 100 recombinant-protein therapeutics, including other hormones and monoclonal antibodies, have become part of clinical practice (Table 1).1 Though small-molecule drugs are more common than recombinant-protein drugs — only 1 of the top 200 prescribed drugs of 2006 (on the basis of prescription volume) was a recombinant protein — protein-based therapeutics have been used to treat diabetes and anemia, as well as relatively rarer conditions, such as rheumatoid arthritis, Gaucher's disease, and multiple sclerosis.2,3 View this table: Table 1. Classes of Approved . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali